share_log

復星醫藥:海外監管公告 - 關於為控股子公司提供擔保的公告

FOSUN PHARMA: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Mar 28 05:52
Summary by Moomoo AI
上海復星醫藥(集團)股份有限公司(「復星醫藥」)於2024年3月28日宣布,為其控股子公司復星醫藥產業發展有限公司(「復星醫藥產業」)向中國工商銀行申請的人民幣9,000萬元流動資金貸款提供連帶責任保證擔保。該擔保是在復星醫藥2022年度股東大會批准的不超過等值人民幣33.3億元的担保额度範圍內。截至公告日,包括此次擔保在內,復星醫藥集團實際對外擔保金額約為人民幣86.26億元,約佔2023年底經審計的歸屬於上市公司股東淨資產的58.15%。復星醫藥產業成立於2001年,為復星醫藥全資子公司,主要經營範圍包括藥品批發、生產、技術服務等。2023年,復星醫藥產業實現營業收入人民幣11.81億元,净利润為負人民幣4.65億元。
上海復星醫藥(集團)股份有限公司(「復星醫藥」)於2024年3月28日宣布,為其控股子公司復星醫藥產業發展有限公司(「復星醫藥產業」)向中國工商銀行申請的人民幣9,000萬元流動資金貸款提供連帶責任保證擔保。該擔保是在復星醫藥2022年度股東大會批准的不超過等值人民幣33.3億元的担保额度範圍內。截至公告日,包括此次擔保在內,復星醫藥集團實際對外擔保金額約為人民幣86.26億元,約佔2023年底經審計的歸屬於上市公司股東淨資產的58.15%。復星醫藥產業成立於2001年,為復星醫藥全資子公司,主要經營範圍包括藥品批發、生產、技術服務等。2023年,復星醫藥產業實現營業收入人民幣11.81億元,净利润為負人民幣4.65億元。
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) ANNOUNCED ON 28 MARCH 2024 THAT ITS HOLDING COMPANY FUSTAR PHARMACEUTICAL INDUSTRY DEVELOPMENT CO., LTD. (“FUSTAR PHARMACEUTICALS”) HAS SECURED A RMB 9,000 MILLION LIQUID CAPITAL LOAN FILED BY THE INDUSTRIAL AND COMMERCIAL BANK OF CHINA WITH A GUARANTEE OF LIABILITY GUARANTEE FOR ITS HOLDING COMPANY FUSTAR PHARMACEUTICALS INDUSTRY DEVELOPMENT CO., LTD. (“FUSTAR PHARMACEUTICALS INDUSTRY”)。 The guarantee is within the range of a concern guarantee of not more than RMB33.3 billion as approved at the 2022 Annual General Meeting of Fustar Pharmaceuticals. As of the announcement date, including this guarantee, Fustar Pharmaceutical Group's actual external guarantee amount was approximately RMB86.26 billion, representing approximately 58.15% of the net assets of listed company shareholders audited at the end of 2023. FUSTAR PHARMACEUTICAL INDUSTRY WAS ESTABLISHED IN 2001 AS A WHOLLY OWNED SUBSIDIARY OF FUSTAR PHARMACEUTICALS. ITS MAIN ACTIVITIES INCLUDE PHARMACEUTICAL WHOLESALING, MANUFACTURING, TECHNICAL SERVICES, ETC. IN 2023, FUSTAR PHARMACEUTICALS INDUSTRY ACHIEVED OPERATING REVENUE OF RMB11.81 MILLION AND NET PROFIT OF NEGATIVE RMB4.65 MILLION.
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) ANNOUNCED ON 28 MARCH 2024 THAT ITS HOLDING COMPANY FUSTAR PHARMACEUTICAL INDUSTRY DEVELOPMENT CO., LTD. (“FUSTAR PHARMACEUTICALS”) HAS SECURED A RMB 9,000 MILLION LIQUID CAPITAL LOAN FILED BY THE INDUSTRIAL AND COMMERCIAL BANK OF CHINA WITH A GUARANTEE OF LIABILITY GUARANTEE FOR ITS HOLDING COMPANY FUSTAR PHARMACEUTICALS INDUSTRY DEVELOPMENT CO., LTD. (“FUSTAR PHARMACEUTICALS INDUSTRY”)。 The guarantee is within the range of a concern guarantee of not more than RMB33.3 billion as approved at the 2022 Annual General Meeting of Fustar Pharmaceuticals. As of the announcement date, including this guarantee, Fustar Pharmaceutical Group's actual external guarantee amount was approximately RMB86.26 billion, representing approximately 58.15% of the net assets of listed company shareholders audited at the end of 2023. FUSTAR PHARMACEUTICAL INDUSTRY WAS ESTABLISHED IN 2001 AS A WHOLLY OWNED SUBSIDIARY OF FUSTAR PHARMACEUTICALS. ITS MAIN ACTIVITIES INCLUDE PHARMACEUTICAL WHOLESALING, MANUFACTURING, TECHNICAL SERVICES, ETC. IN 2023, FUSTAR PHARMACEUTICALS INDUSTRY ACHIEVED OPERATING REVENUE OF RMB11.81 MILLION AND NET PROFIT OF NEGATIVE RMB4.65 MILLION.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more